Janux Therapeutics Announces Development Candidate Nomination

Milestone payment of $35 million triggered under Bristol Myers Squibb collaboration

Apr. 1, 2026 at 6:02pm

Got story updates? Submit your updates here. ›

Janux Therapeutics, a clinical-stage biopharmaceutical company, has announced the nomination of a development candidate under its collaboration with Bristol Myers Squibb. This nomination has triggered a $35 million milestone payment from Bristol Myers Squibb.

Why it matters

The development candidate nomination is a significant milestone for Janux, as it demonstrates the progress of their novel immunotherapy pipeline and the value of their collaboration with the pharmaceutical giant Bristol Myers Squibb. This milestone payment will provide additional funding to support Janux's continued research and development efforts.

The details

Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel immunotherapies. The company has a collaboration agreement with Bristol Myers Squibb, and the nomination of this development candidate triggers a $35 million milestone payment from Bristol Myers Squibb to Janux.

  • Janux Therapeutics announced the development candidate nomination on April 1, 2026.

The players

Janux Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies.

Bristol Myers Squibb

A global biopharmaceutical company and one of the world's leading diversified specialty biopharmaceutical companies.

Got photos? Submit your photos here. ›

The takeaway

This development candidate nomination and the associated $35 million milestone payment demonstrate the progress and value of Janux Therapeutics' collaboration with Bristol Myers Squibb, providing additional funding to support the company's continued research and development efforts in the field of novel immunotherapies.